Insights on the Burden of Hidradenitis Suppurativa from a Patient Survey

Christos C Zouboulis, Iltefat Hamzavi, Heather Lapidus Glassner, Ingrid Pansar, Hadar Lev-Tov

1Dessau Medica Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany; 2Henry Ford Medical Center, Detroit, MI, USA; 3MyHealthTeams, San Francisco, CA, USA; 4UCB Pharma, Brussels, Belgium; 5University of Miami, Miami, FL, USA

Learning Objective: Understand the disease burden of HS from a patient perspective

Take Away Messages:
• Respondents indicated a high disease burden from the symptoms and psychological impact of HS
• There remains a high unmet need for safe, effective treatments to reduce the burden of disease felt by patients

Disclosures: C. Zouboulis: Honoraria as an advisor and speaker for studies or lectures associated with HS, but not with the current study, from AbbVie, Idorsia, Incyte, InflaRx, Janssen, Novartis, Regeneron and UCB Pharma. His department has received grants from AbbVie, InflaRx, Novartis and UCB Pharma for his participation as an investigator; I. Hamzavi: Consultant for Incyte, Clarify Medical and Pfizer (fees paid to institution); Consultant for Boehringer Ingelheim, Janssen and UCB (fees paid to self); Principal Investigator for Pfizer, Bayer, Lenicura and Incyte (fees paid to institution), and sub-investigator for Chemocentryx; Served on Advisory Board for AbbVie (no compensation received) and as president of the HS Foundation (non-compensated role); H. Lapidus Glassner: Employee of MyHealthTeams, who received funding from UCB Pharma to conduct this survey; I. Pansar: Employee of UCB Pharma; H. Lev-Tov: No relevant conflicts to declare.
Plain Language Summary

Why was this study needed?

There is very little information available on how HS affects patients’ daily lives, told from the point of view of the patients themselves

What did this study show?

Of the patients who participated in the survey:

- 6/10 said that the painful, swollen, boils, lumps and abscesses were the symptom that affected their lives most
- 7/10 said that they suffered from either anxiety or depression
- 9/10 were uncomfortable with the idea of intimacy, and nearly 9/10 said that the disease affected the clothing that they chose to wear

Why is this important?

This study shows that having HS has a large impact on patients’ day-to-day lives, and highlights that better treatments are needed so that they can enjoy a better quality of life

---

HS: hidradenitis suppurativa
Patients with hidradenitis suppurativa (HS) endure painful, inflammatory nodules and abscesses, which can rupture and form draining abscesses and draining tunnels.

Extensive scarring and fibrosis in sensitive locations can lead to contractures and limb mobility limitations.

The pain and malodorous discharge can have a substantial effect on patients’ quality of life.

Despite this, real-world, patient-reported data on the disease burden of HS are lacking.

We aimed to assess the social, psychological and physical disease burden of HS using a patient questionnaire.
Survey Methodology

Online survey (November 5 – December 20 2020)
• Questions on demographics, treatment, and experience of HS: symptoms, impact on daily life, burden of disease

Recruitment via:
• Emails to members of myHSteam
• Posts on myHSteam Facebook page, Google ads and Quora ads

240 respondents completed the survey:
• ≥21 years of age, with a confirmed/suspected diagnosis of HS
• 67% recruited from myHSteam (primarily via email invitations) (n=164)
• 33% recruited from Google AdWords (n=65), Facebook (n=5), and Quora (n=6)

Only results from female participants (n=221, 92%) are shown
**Respondent Characteristics (Female population)**

**Age**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Percentage</th>
<th>n=</th>
</tr>
</thead>
<tbody>
<tr>
<td>21-29</td>
<td>18%</td>
<td>40</td>
</tr>
<tr>
<td>30-39</td>
<td>28%</td>
<td>61</td>
</tr>
<tr>
<td>40-49</td>
<td>27%</td>
<td>60</td>
</tr>
<tr>
<td>50-59</td>
<td>19%</td>
<td>41</td>
</tr>
<tr>
<td>60-71</td>
<td>9%</td>
<td>19</td>
</tr>
</tbody>
</table>

Average age: 42 years

**Country**

- **United States**: 49% (n=108)
- **United Kingdom**: 24% (n=52)
- **Canada**: 12% (n=27)

4% South Africa; 3% Australia; 2% Ireland; 1% Netherlands; 1% New Zealand; 5% Other

**Race/Ethnicity**

- **United States**:a
  - 69% White/Caucasian (n=74)
  - 25% Black/African-American (n=27)
  - 8% Latina/Hispanic (n=9)

- **United Kingdom**:
  - 90% White British (n=47)

All other groupsb ≤3%

aIn the US the question was a multiple response, and so sums to >100%; bOther groups consisted of US: 1% Asian, 3% Other; UK: 2% Mixed/multiple, 2% Black/Black British/Caribbean/African, 2% Asian/Asian British, 2% Other, 2% Prefer not to say.

**Diagnosis**

- **No, I have not been diagnosed yet, but I think I have it**: 16% (n=36)
- **Yes, a doctor has diagnosed me**: 84% (n=185)

Female population; n=221.
### Respondent Characteristics (Female Population)

#### Self-Identified Stage of HS

<table>
<thead>
<tr>
<th>Stage</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>13%</td>
</tr>
<tr>
<td>Moderate</td>
<td>41%</td>
</tr>
<tr>
<td>Severe</td>
<td>41%</td>
</tr>
<tr>
<td>Not sure</td>
<td>5%</td>
</tr>
</tbody>
</table>

#### Frequency of Self-Identified Flare Ups

- **On a daily basis**: 25%
- **On a weekly basis**: 27%
- **On a monthly basis**: 27%
- **Every few months or less**: 20%
- **Not at all**: 1%

---

**Q4.** Overall, would you describe your HS as mild, moderate or severe? Note: severity was self-reported and not physician-assessed. Female population; n=221.

**Q5.** How often have you experienced periods of increased HS symptoms (or flare-ups) in the past 12 months? Note: flares were self-reported and not physician-assessed. Female population; n=221.
Q6. Where on your body do you experience HS? Please select all that apply.
Female population; n=221.

- Breasts (under or between): 47%
- Genital area: 68%
- Groin: 71%
- Thighs: 44%
- Head/neck: 13%
- Armpits: 65%
- Perennial area/anus: 30%
- Exterior of buttocks: 36%
Q7. What symptoms do you experience from your HS? Please select all that apply.

Female population; n=221.

On average, respondents experienced **9–10** different symptoms.
Q8. Which symptoms have the greatest impact on your daily life? Please choose no more than three symptoms. Note: question was multiple response, so the total sums to more than 100%.

Female population; n=221, or n=91 for the severe HS group. Note that severity was self-identified.
Q30. Which of the following (if any) health issues or conditions do you experience besides HS? Please select all that apply.
Female population; n=221. Health conditions were self-assessed and not required to be physician-diagnosed.

- Anxiety: 61%
- Depression: 53%
- Obesity: 50%
- Chronic pain: 32%
- High blood pressure: 22%
- Diabetes: 15%
- Polycystic ovary syndrome: 14%
- Psoriasis: 13%
- Fibromyalgia: 9%
- Rheumatoid arthritis: 8%
- Spondylitis, psoriatic arthritis: 7%
- Crohn's disease, ulcerative colitis: 6%
- Cardiovascular/heart disease: 5%
- Metabolic syndrome: 4%

71% of women indicate either anxiety or depression; 43% indicated both anxiety and depression.
Q26. Please help us understand the impact living with HS has had on your life. How much do you agree or disagree with each of the following statements?  
Female population; n=221.
Conclusions

Targeting individuals who participate in a community for HS resulted in higher survey participation rates than individuals recruited from general web sources.

The 221 female respondents experienced high disease burden from the symptoms and psychological impact of HS.

There remains a high unmet need for safe, effective treatments to reduce the burden of disease felt by patients.

Acknowledgements: The authors acknowledge Susanne Wiegratz, UCB Pharma, Monheim, Germany, for publication coordination. Editorial services for this presentation were provided by Helen Chambers, DPhil, Costello Medical Consulting (Cambridge, UK) funded by UCB Pharma.